A clinical trial of Intravenous Glutathione along with standard treatment in Moderate COVID-19 Pneumonia Patients.
- Conditions
- Health Condition 1: B972- Coronavirus as the cause of diseases classified elsewhere
- Registration Number
- CTRI/2021/01/030793
- Lead Sponsor
- Zuventus Healthcare Limited
- Brief Summary
Not available
- Detailed Description
Not available
Recruitment & Eligibility
- Status
- Completed
- Sex
- Not specified
- Target Recruitment
- 240
1. Patients with laboratory confirmation of infection with SARS-CoV-2 by positive RT-PCR.
2. Patients with moderate COVID-19 (According to Clinical Management Protocol: COVID 19, Govt. of India).
-Patients with presence of clinical features of dyspnea and or hypoxia, fever, cough, including SpO2 <94% (range 90-94%) on room air
-Respiratory Rate �24 per minute
-Pneumonia with no signs of severe disease
3. Symptomatic adult male or non-pregnant female (�18 years)
4. Voluntarily participating in the clinical study and patients or legal representative willing to sign informed consent.
1. Asymptomatic COVID-19 patients.
2. Patients with known hypersensitivity to glutathione or related drugs.
3. Patients enrolled in any other investigational drug studies in COVID-19.
4. Severe infection and need for invasive or non-invasive ventilator support.
5. Pregnant or lactating women
Study & Design
- Study Type
- Interventional
- Study Design
- Not specified
- Primary Outcome Measures
Name Time Method
- Secondary Outcome Measures
Name Time Method